Factors Influencing Participation in PRADO and Telemedicine Interventions in Heart Failure

Patients with heart failure (HF), after hospitalization, present a marked fragility: in France, in the first year, 29% die and 45% are rehospitalized for HF. Interventions improving the coordination of care actors at the time of discharge from hospitalization have been tested and have shown in preliminary studies a reduction in rehospitalizations for HF (relative risk (RR) from 0.51 to 0.74) and all-cause mortality (RR 0.75 to 0.87).

Among these promising devices, two have recently been deployed nationwide.

* The return home program for IC patients (PRADO IC), set up by the Health Insurance, aims to facilitate the return and stay at home after hospitalization. It offers assistance with the initiation of outpatient medical follow-up, nursing follow-up for 2 to 6 months depending on the severity of the patient, and a follow-up log facilitating the exchange of information. It is based on the assumption that these actions will improve the coordination of care between the hospital and the city, and between home nurses and doctors. In addition, nurses reinforce therapeutic patient education (TPE), whether or not it is initiated in a setting dedicated to TPE. * At the same time, as part of the ETAPES program of the Health Insurance, the deployment of telemedicine for remote monitoring of heart failure pursues a comparable objective of reducing rehospitalizations. It is based on the hypothesis that the early signs of cardiac decompensation can be diagnosed by telemonitoring and trigger earlier and therefore less aggressive management for similar effectiveness.

These two systems are widely deployed on a national scale, and are intended to be universal.

However, three points can call into question the effectiveness of this deployment: their evaluation is often difficult, the extrapolability of randomized studies to health systems and different populations is low, and the complementarity of two independently constructed programs has never been been studied so far.

1. The preliminary data concerning the PRADO were epidemiological, historical, comparative before-elsewhere, on the SNIIRAM (National health insurance inter-scheme information system) databases, without optimal consideration of clinical and cultural confounding factors. 2. The acceptability of these programs by all health professionals (and therefore how they choose to deploy such and such a system for a given patient) and patients in the French context is not known. 3. The PRADO system and telemedicine solutions, acting differently, could be synergistic and therefore multiply the benefits obtained. However, in practice, some patients experience these programs as intrusive, and it is possible that their adherence is in fact all the worse when two programs are implemented. Similarly, from the prescriber's point of view, the way in which the various possible combinations are chosen is unknown.

The answer to these three questions is necessary to guide the most effective deployment of these programs nationwide.

Our hypothesis is that adherence to care transition and telemedicine programs, and therefore their effectiveness, may depend on their association, as well as socio-demographic, cultural, and geographical factors.

• Number of non-participation of patients [Срок оценки: At inclusion]
• Number of non-participation of patients [Срок оценки: through study completion, an average of 6 months]
• Percentage effectiveness of pathology programs at 1 month [Срок оценки: between inclusion and 1 month]
• Percentage effectiveness of pathology programs at 1 month [Срок оценки: between inclusion and 1 month]
• Percentage effectiveness of pathology programs at 1 month [Срок оценки: between inclusion and 1 month]
• Percentage effectiveness of pathology programs at 1 month [Срок оценки: between inclusion and 1 month]
• Percentage effectiveness of pathology programs at 6 months [Срок оценки: between inclusion and 6 months]
• Percentage effectiveness of pathology programs at 6 months [Срок оценки: between inclusion and 6 months]
• Percentage effectiveness of pathology programs at 6 months [Срок оценки: between inclusion and 6 months]
• Percentage effectiveness of pathology programs at 6 months [Срок оценки: between inclusion and 6 months]
• percentage of effectiveness on the course of care at 6 months [Срок оценки: between inclusion and 6 months]
• percentage of effectiveness on the course of care at 6 months [Срок оценки: between inclusion and 6 months]